Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Krystal Biotech (KRYS) Assets Average (2021 - 2025)

Historic Assets Average for Krystal Biotech (KRYS) over the last 5 years, with Q4 2025 value amounting to $1.3 billion.

  • Krystal Biotech's Assets Average rose 2628.51% to $1.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.3 billion, marking a year-over-year increase of 2628.51%. This contributed to the annual value of $1.2 billion for FY2025, which is 2750.19% up from last year.
  • Per Krystal Biotech's latest filing, its Assets Average stood at $1.3 billion for Q4 2025, which was up 2628.51% from $1.2 billion recorded in Q3 2025.
  • Krystal Biotech's Assets Average's 5-year high stood at $1.3 billion during Q4 2025, with a 5-year trough of $443.3 million in Q2 2021.
  • For the 5-year period, Krystal Biotech's Assets Average averaged around $781.5 million, with its median value being $737.2 million (2023).
  • Per our database at Business Quant, Krystal Biotech's Assets Average plummeted by 1229.7% in 2023 and then surged by 5332.07% in 2024.
  • Quarter analysis of 5 years shows Krystal Biotech's Assets Average stood at $538.7 million in 2021, then rose by 5.33% to $567.4 million in 2022, then skyrocketed by 41.76% to $804.4 million in 2023, then grew by 26.7% to $1.0 billion in 2024, then rose by 26.29% to $1.3 billion in 2025.
  • Its Assets Average was $1.3 billion in Q4 2025, compared to $1.2 billion in Q3 2025 and $1.1 billion in Q2 2025.